Most high-income countries are aggressively engaged in the collection and research
evaluation of convalescent plasma as a specific passive immunotherapy for treatment of …

• Although early reports have been promising1, 2, the safety and efficacy of COVID-19
convalescent plasma as a treatment for COVID-19 are unproven at this time. However …

Points to consider in the preparation and transfusion of COVID‐19 convalescent plasma Page 1
Accepted Article This article has been accepted for publication and undergone full peer review …

Coronavirus disease-2019 (COVID-19), caused by severe acute respiratory coronavirus 2
(SARS-CoV-2), has rapidly spread since its first declaration by the World Health …

Abstract Coronavirus disease 2019 (COVID-19) is a disease spreading rapidly in Sudan, the
rest of the African continent and the world with no known definitive treatment or vaccines …

As yet, there is no specific therapy for covid-19. Thus, as an alternative, there is the
transfusion of plasma obtained from individuals who are convalescent from covid-19 …

Background The lack of definitive treatment or preventative options for COVID‐19 led many
clinicians early on to consider convalescent plasma (CCP) as potentially therapeutic …

• There is some evidence for favourable outcomes in patients who have received COVID-19
convalescent plasma, but it is not definitive. WHO recognizes COVID-19 convalescent …

168 Letter to the Editor/Transfusion Clinique et Biologique 27 (2020) 165–171 tional studies
have stimulated global interest in the organisation of collection systems for this …

Background and objectives COVID‐19 convalescent plasma (CCP) has been used,
predominantly in high‐income countries (HICs) to treat COVID‐19; available data suggest …